利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.024 秒)

    TCF mutant
    3.
    发明授权
    TCF mutant 失效
    TCF突变体

    公开(公告)号：US06399744B1

    公开(公告)日：2002-06-04

    申请号：US08700519

    申请日：1996-08-26

    申请人： Masahiko Kinosaki ,  Kyoji Yamaguchi ,  Fumie Kobayashi ,  Masaaki Goto ,  Akihiko Murakami ,  Masatsugu Ueda ,  Yasushi Yamashita ,  Kanji Higashio

    发明人： Masahiko Kinosaki ,  Kyoji Yamaguchi ,  Fumie Kobayashi ,  Masaaki Goto ,  Akihiko Murakami ,  Masatsugu Ueda ,  Yasushi Yamashita ,  Kanji Higashio

    IPC分类号： C07K1400

    CPC分类号： C07K14/4753 ,  A61K38/00

    摘要： The present invention relates to a TCF mutant having a novel amino acid sequence which is obtained by mutagenesis of one or more amino acid between N-terminus and the first kringle of the amino acid sequence of native TCF and has lowered affinity to heparin and/or elevated biological activity. The present TCF mutant is prepared by gene manipulation of TCF. The TCF mutants of the present invention have proliferative activity and/or growth stimulative activity in hepatocyte and beneficial as a therapeutic agent for various hepatic diseases and an antitumor agent.

    摘要翻译： 本发明涉及具有新氨基酸序列的TCF突变体，其通过在天然TCF的氨基酸序列的N末端与第一个三环体之间的一个或多个氨基酸的诱变获得，并且具有降低的对肝素和/或 升高的生物活性。 本发明的TCF突变体通过TCF的基因操作来制备。 本发明的TCF突变体在肝细胞中具有增殖活性和/或生长刺激活性，并且作为各种肝脏疾病和抗肿瘤剂的治疗剂是有益的。

    Tissue plasminogen-activating factor and nonoclonal antibody
    5.
    发明授权
    Tissue plasminogen-activating factor and nonoclonal antibody 失效
    组织致细胞因子激活因子和非分子抗体

    公开(公告)号：US5112754A

    公开(公告)日：1992-05-12

    申请号：US483800

    申请日：1990-02-23

    申请人： Akira Suzuki ,  Yasuharu Itagaki ,  Kanji Higashio

    发明人： Akira Suzuki ,  Yasuharu Itagaki ,  Kanji Higashio

    IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  C07K1/22 ,  C07K14/005 ,  C07K14/195 ,  C07K14/745 ,  C07K16/00 ,  C07K16/40 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577

    CPC分类号： C07K14/745 ,  C07K16/40 ,  A61K38/00

    摘要： A novel tissue plasminogen activator having the following characteristics: molecualr weight of 65,000-72,000 Daltons as measured by SDS-PAGE electrophoresis using at 7.5% agarose gel; plasminogen activator specific activity of about 10.4.times.10.sup.4 IU/mg, wherein specific activity is defined as the ratio of fibrinolytic activity of purified t-PA measured on fibrin-agarose plates to milligrams of protein; about 83.1% absorption of t-PA by a fibrin-Sepharose column when applied; binds to a Concanavalin A column when applied; the fibrinolytic activity is substantially undiminished by heating at 60.degree. C. for 60 minutes or 95.degree. C. for 5 minutes relative to unheated t-PA; unreactive with polyclonal antisera raised against urokinase; the fibrinolytic activity is substantially stable at pH 5-10; exhibits fibrinolytic activity at pH 7.5-9.0 and temperature 39.degree.-41.degree. C.; a Km value of about 1.16.times.10.sup.-3 mol/liter and a V.sub.max of about 11.7.times.10.sup.-8 mol/liter for substrate S-2288; and fibrinolytic activity is inhibited by Co.sup.2+ Zn.sup.2+, Cd.sup.2+, Hg.sup.2+, Ni.sup.2+ and Cu.sup.2+.

    摘要翻译： 具有以下特征的新型组织纤溶酶原激活物：通过使用7.5％琼脂糖凝胶的SDS-PAGE电泳测量的分子量为65,000-72,000道尔顿; 约10×10 14 IU / mg的纤溶酶原激活剂比活度，其中比活性定义为在纤维蛋白 - 琼脂糖平板上测量的纯化t-PA的纤维蛋白溶解活性与毫克蛋白质的比例; 应用时纤维蛋白 - 琼脂糖凝胶柱吸收t-PA约83.1％; 应用时可结合伴刀豆球蛋白A柱; 相对于未加热的t-PA，通过在60℃加热60分钟或95℃5分钟，纤维蛋白溶解活性基本上没有减弱; 与尿激酶相关的多克隆抗血清无反应; 纤维蛋白溶解活性在pH 5-10时基本稳定; 在pH 7.5-9.0和39°-41℃下呈现纤维蛋白溶解活性。 对于基材S-2288，Km值为约1.16×10-3摩尔/升，Vmax为约11.7×10-8摩尔/升; Co2 ++ L，Zn2 +，Cd2 +，Hg2 +，Ni2 +和Cu2 +可抑制纤维蛋白溶解活性。

    Agent for preventing and/or treating multiple organ failure
    7.
    发明授权
    Agent for preventing and/or treating multiple organ failure 失效
    用于预防和/或治疗多器官衰竭的药剂

    公开(公告)号：US07306791B2

    公开(公告)日：2007-12-11

    申请号：US10317011

    申请日：2002-12-11

    申请人： Hirohiko Arisawa ,  Hiroaki Masunaga ,  Hiromi Ogawa ,  Kanji Higashio

    发明人： Hirohiko Arisawa ,  Hiroaki Masunaga ,  Hiromi Ogawa ,  Kanji Higashio

    IPC分类号： A61K45/00 ,  A61K38/16 ,  C07K17/00

    CPC分类号： A61K38/1833 ,  Y10S514/97

    摘要： The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.

    摘要翻译： 本发明提供了预防和/或治疗多器官衰竭的方法，包括施用治疗有效量的包含肿瘤细胞因子-II（TCF-II）或肝细胞生长因子（HGF）的药剂的步骤。 本发明的方法可用于预防和/或治疗由烧伤，弥漫性血管内凝血（DIC），循环衰竭，出血性休克，感染性疾病，急性胰腺炎，缺血性障碍，肝肾综合征，胃肠道引起的多器官功能衰竭的发展 出血，营养代谢失败，终末期癌症，获得性免疫缺陷综合征（AIDS），由辐射影响导致的系统性病症恶化和恶病质。